Wegovy pill: oral semaglutide UK availability, dose and side effects

Is there now a Wegovy pill in the UK?

Yes. On 11 June 2026, the Medicines and Healthcare products Regulatory Agency approved semaglutide tablets under the Wegovy brand for weight loss and weight management in adults in the UK. The MHRA described it as the UK’s first GLP-1 receptor agonist tablet approved for this use. [1]

How much will the Wegovy pill cost?

The exact Wegovy pill price in the UK has not yet been confirmed. However, it is expected that Wegovy tablets will be priced similarly to Wegovy injections which start around £99 per month for the lowest dose, although this may vary depending on the dose, supplier pricing, pharmacy dispensing costs, and the level of clinical support included.

At Lotus Weight Loss, we will confirm the Wegovy pill cost as soon as UK pricing and availability are finalised. If you are interested in starting oral Wegovy, you can join our waitlist and we will update you when the Wegovy pill becomes available.

The Wegovy pill will be a prescription-only medicine, so the total cost may include an online consultation, prescriber review, ongoing monitoring, and medication supply.

What is the Wegovy pill?

The Wegovy pill is a tablet form of semaglutide. Semaglutide is a GLP-1 receptor agonist, which means it acts like glucagon-like peptide-1, a hormone involved in appetite, fullness, digestion and blood sugar regulation. [1][2]

In weight management, semaglutide acts on areas of the brain involved in appetite regulation. This can help some people feel fuller for longer, feel less hungry and experience fewer cravings. It is not a stimulant, a fat burner, or a cosmetic weight-loss pill. Wegovy is a prescription medicine used alongside a reduced-calorie diet and increased physical activity. [1][3]

Until now, Wegovy has mainly been known in the UK as a weekly injection. The tablet gives eligible adults another format: oral semaglutide taken once daily. That may be useful for people who strongly prefer tablets, but it also creates a different practical burden because timing and absorption matter.

Who may be eligible for Wegovy tablets?

Based on the MHRA approval, Wegovy tablets may be prescribed alongside a reduced-calorie diet and increased physical activity to adults in the UK who have either:

• a BMI of 30 or above; or
• a BMI between 27 and 30 and at least one weight-related comorbidity. [1]

A weight-related comorbidity may include a condition such as high blood pressure, abnormal cholesterol, obstructive sleep apnoea, cardiovascular disease, or another obesity-related health concern. Eligibility is not based on BMI alone. A prescriber also needs to consider whether semaglutide is suitable for the individual person, including current medicines, previous GLP-1 use, diabetes medicines, digestive symptoms, family-planning circumstances, breastfeeding, surgery plans and any history of pancreatitis or serious eye symptoms. [2][3][4]

NHS criteria may be narrower than the medicine’s marketing authorisation. Existing NICE guidance for injectable semaglutide in weight management limits use to specific NHS settings and eligibility criteria, including specialist weight management services. NICE also advises lower BMI thresholds for some ethnic family backgrounds because health risks can develop at lower BMI levels. [5]

When will I be able to order the Wegovy pill from Lotus?

The Wegovy pill has only recently been approved in the UK by the medicines regulator, the MHRA. It is expected to become available to order from Lotus Weight Loss at the start of July, subject to confirmed UK supply and pharmacy availability.

If you are interested in starting the Wegovy pill, switching from Wegovy or Mounjaro injections, or restarting treatment after a break, please join our priority update list. We’ll contact you as soon as we have confirmed launch details, pricing, and ordering information.

Join the Wegovy pill waitlist here: https://www.lotusweightloss.co.uk/pages/weight-loss-pill

How do you take the Wegovy pill?

The Wegovy pill is not taken like an ordinary daily tablet. Oral semaglutide is difficult for the body to absorb, so the timing instructions matter.

The MHRA says semaglutide tablets should be taken whole on an empty stomach after fasting for at least eight hours, with a sip of water. After taking the tablet, you should not eat or drink for at least 30 minutes. Eating or drinking sooner than this can lower absorption. [1]

Important: the 30-minute window includes coffee, tea, breakfast, supplements and other oral medicines. Anyone who takes morning medicines such as levothyroxine, anticoagulants, blood pressure tablets or diabetes medicines should ask their prescriber how to organise the timing safely.

A practical routine may look like this:

• take the tablet when you wake, after an overnight fast of at least eight hours;
• swallow it whole with water only;
• wait at least 30 minutes before eating, drinking, or taking other oral medicines;
• take it in the same way each day;
• check the patient leaflet that comes with the medicine and follow the prescriber’s instructions.

This is one of the biggest practical differences between Wegovy tablets and Wegovy injections. The injection is weekly and does not require a daily fasting window. The tablet avoids needles, but it asks more from the patient’s morning routine.

What dose is the Wegovy pill?

The MHRA states that the Wegovy tablet dosing schedule starts at 1.5mg once daily. The dose then increases to 4mg, 9mg and 25mg, with a minimum duration of one month at each dose level. [1]

The gradual increase is there for tolerability. GLP-1 medicines commonly cause digestive side effects, especially when starting treatment or increasing dose. Increasing too quickly may make nausea, vomiting, diarrhoea or poor tolerance more likely. [1][2]

The 25mg tablet is the maintenance dose discussed in the MHRA approval and OASIS 4 evidence. It should not be confused with older oral semaglutide doses used for type 2 diabetes under the Rybelsus brand. [1][8]

How much weight can you lose with oral semaglutide?

The main clinical evidence for the Wegovy pill comes from the OASIS 4 trial. In that phase 3 trial, adults with obesity or overweight and at least one weight-related complication were assigned to oral semaglutide 25mg once daily or placebo, alongside lifestyle intervention, for 64 weeks. The trial excluded people with diabetes. [6][7]

The published trial reported substantially greater average weight loss with oral semaglutide 25mg than with placebo. One analysis reported an estimated mean body-weight change at 64 weeks of about -13.6% with oral semaglutide compared with -2.2% with placebo. Novo Nordisk also reported an adherence-based analysis of -16.6% with oral semaglutide 25mg compared with -2.7% with placebo. [6]

Those figures should be used carefully. They are averages from a clinical trial, not a guarantee for an individual patient. Some people lose more, some lose less, and some stop treatment because of side effects or other reasons. Results also depend on dose tolerance, adherence, nutrition, activity, baseline weight, medical history and the quality of support around the medicine.

Is the Wegovy pill better than the Wegovy injection?

Not automatically. It is more accurate to think of Wegovy tablets and Wegovy injections as different formats with different trade-offs.

Feature	Wegovy pill	Wegovy injection
Active ingredient	Semaglutide	Semaglutide
Route	Tablet taken by mouth	Subcutaneous injection
Frequency	Once daily	Once weekly
Timing rules	Empty stomach after at least eight hours fasting, then at least 30 minutes before food, drink or other oral medicines	No daily fasting rule linked to dosing
Main practical advantage	Needle-free	Weekly routine
Main practical challenge	Poor timing can reduce absorption	Requires injection technique and correct storage
May suit	People who strongly prefer tablets and can follow the morning routine	People who prefer weekly dosing or find the tablet routine impractical

For some people, avoiding injections will matter. For others, a weekly injection may be simpler than a tablet that has to be taken under strict conditions every day. The right choice is the one that fits the person’s health, treatment history, preferences and ability to use the medicine correctly.

Can you switch from Wegovy injections to Wegovy tablets?

Yes, some patients can switch from Wegovy injections to Wegovy tablets, but this must be reviewed by a prescriber.

The official switching position is strongest for patients already stable on Wegovy 2.4mg weekly, who may be able to move to Wegovy 25mg tablets once daily one week after their last injection.

Wegovy injection to Wegovy pill switching guide

If you are already using Wegovy injections, you may be able to switch to the Wegovy pill. The table below shows the estimated Wegovy pill dose that may be recommended based on your current Wegovy injection dose.

Current Wegovy injection dose	Recommended Wegovy pill dose
0.25mg weekly	4mg once daily
0.5mg weekly	9mg once daily
1mg weekly	9mg once daily
1.7mg weekly	25mg once daily
2.4mg weekly	25mg once daily
7.2mg weekly	25mg once daily

Note: This switching guide is taken from the Wegovy pill Summary of Product Characteristics from the manufacturer, which is expected to be published on the MHRA products website within 7 days of approval: https://products.mhra.gov.uk/

This switching method is considered off-label, meaning it has not been formally evaluated in clinical trials. However, real-world data and clinical experience when switching between GLP-1 medicines suggest that many patients tolerate the transition well, with side effects generally limited to those commonly seen with GLP-1 treatments, such as nausea, constipation, diarrhoea, reflux, or reduced appetite.

Your Wegovy pill dose should always be confirmed by a prescriber after reviewing your current dose, side effects, medical history, and how long you have been using Wegovy injections. If you are a new customer then you can complete our online consultation form which will guide you through the switching process, and if you are an existing customer, you can log in to your Lotus account and click 'Reorder' and then choose to change your medication.

Switching may make sense for someone who dislikes injections, travels frequently, or would be more consistent with a tablet. It may make less sense for someone who is doing well on a weekly injection, struggles with morning routines, takes several morning medicines, or has previously had significant digestive side effects.

Can I switch from Mounjaro to the Wegovy pill?

Yes, patients may be able to switch from Mounjaro to the Wegovy pill, but this is not a direct like-for-like dose conversion.

Mounjaro contains tirzepatide, which works on both GIP and GLP-1 receptors. Wegovy contains semaglutide, which is a GLP-1 receptor agonist. Because they are different medicines, the doses cannot be matched exactly.

Mounjaro to Wegovy pill switching guide

If you are currently using Mounjaro, the table below shows the estimated Wegovy pill dose that may be recommended based on your current Mounjaro dose.

Current Mounjaro dose	Recommended Wegovy pill dose
2.5mg weekly	1.5mg once daily
5mg weekly	4mg once daily
7.5mg weekly	9mg once daily
10mg weekly	9mg once daily
12.5mg weekly	25mg once daily
15mg weekly	25mg once daily

This switching guide is based on clinical judgement and extrapolated dose comparisons. Switching from Mounjaro to the Wegovy pill is considered off-label, meaning it has not been formally evaluated in clinical trials.

However, real-world data and clinical experience when switching between GLP-1 medicines suggest that many patients tolerate the transition well, with side effects generally limited to those commonly seen with GLP-1 treatments, such as nausea, constipation, diarrhoea, reflux, or reduced appetite.

You should not use Mounjaro and Wegovy together. Your prescriber will advise when to stop Mounjaro and when to start Wegovy tablets, based on your current dose, side effects, treatment history, and weight loss progress.

If you are a new customer then you can complete our online consultation form which will guide you through the switching process, and if you are an existing customer you can log in to your Lotus account and click 'Re-order' and then choose to change your medication.

Is the Wegovy pill the same as Rybelsus?

No. This is an important distinction because both involve oral semaglutide, but they are not interchangeable weight-loss products.

Rybelsus is an oral semaglutide medicine used for adults with type 2 diabetes. Wegovy is the semaglutide brand used for weight management and, in some circumstances, cardiovascular risk reduction. NHS patient information describes semaglutide as being used for obesity under the Wegovy brand and for type 2 diabetes under Ozempic and Rybelsus. [8][9]

The Wegovy pill should not be described as “Rybelsus for weight loss”. Patients should not try to use diabetes semaglutide tablets as a substitute for a prescribed weight-management medicine.

Wegovy pill vs Mounjaro

The Wegovy pill and Mounjaro are both prescription medicines used in weight management, but they are not the same medicine.

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors. The Wegovy pill is taken once daily by mouth. Mounjaro is currently used as a weekly injection. [2]

The patient-facing comparison is often framed as tablet convenience versus injection strength, but that is too simple. Treatment choice should consider eligibility, previous response, side effects, diabetes status, dose availability, cost, support model and patient preference.

It would be misleading to say Wegovy tablets are automatically better because they are oral. It would also be misleading to say Mounjaro is always the better choice because many people see strong results on tirzepatide. These are different medicines with different evidence bases and practical demands.

Wegovy pill vs Foundayo

Foundayo is the US brand name for orforglipron, an oral GLP-1 medicine developed by Eli Lilly. The US Food and Drug Administration approved Foundayo for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related comorbidity, on 1 April 2026. [10]

For UK patients, the more important point is that Foundayo is not currently a UK-licensed weight-loss medicine. It should not be treated as a routine UK alternative to Wegovy tablets unless and until it has the relevant UK authorisation and prescribing route.

The practical difference, based on US information, is that Foundayo can be taken without the same food and water restrictions, while Wegovy tablets have strict fasting and 30-minute waiting instructions. That may become an important comparison if orforglipron is approved in the UK, but this Wegovy guide should not overreach into an orforglipron article. [1][10]

What are the side effects of the Wegovy pill?

The most common side effects reported by the MHRA for semaglutide tablets are gastrointestinal: nausea, diarrhoea, constipation and vomiting. These are common across GLP-1 medicines and are often most noticeable when starting treatment or increasing dose. [1][2]

Some digestive side effects can often be managed by eating smaller portions, slowing down at meals, reducing very high-fat meals, drinking enough fluid and discussing dose timing with the prescriber. But side effects should not be dismissed if they are severe, persistent, unusual or getting worse.

Symptom or situation	Why it matters	What to do
Severe or persistent abdominal pain, especially if it spreads to the back	This can be a warning sign of pancreatitis, which has been reported with GLP-1 medicines.	Seek urgent medical help. Do not continue treatment and simply wait for it to pass. [2][4]
Repeated vomiting or diarrhoea, inability to keep fluids down, dizziness or passing much less urine	Fluid loss can cause dehydration and may affect kidney function.	Contact your prescriber promptly. Seek urgent help if symptoms are severe or you cannot keep fluids down. [2][4]
Upper abdominal pain with fever, yellowing of the skin or eyes, pale stools or dark urine	These can be warning signs of gallbladder, bile duct or liver-related problems.	Seek urgent medical advice. [3][4]
Sudden vision loss, sudden blurred vision, or eyesight getting worse quickly	Semaglutide product information has been updated to include a very rare risk of non-arteritic anterior ischaemic optic neuropathy. Diabetic eye disease can also need urgent assessment.	Attend eye casualty if available, call NHS 111, contact a doctor urgently, or attend A&E if you cannot get help quickly. [2][11]
Sweating, shaking, dizziness, palpitations, confusion or symptoms of low blood sugar	Hypoglycaemia is more likely if semaglutide is used with insulin or certain diabetes medicines.	Follow your diabetes plan and contact your diabetes team or prescriber. Seek urgent help if symptoms are severe. [2][4]
Pregnancy, trying to conceive or breastfeeding	GLP-1 medicines should not be used during pregnancy or breastfeeding, and semaglutide should be stopped before trying to become pregnant.	Tell your prescriber straight away. Do not start, continue or restart treatment without medical advice. [2]
Surgery, dental procedures with sedation, or general anaesthetic	GLP-1 medicines can delay gastric emptying, which may matter for anaesthesia or deep sedation.	Tell the surgical, anaesthetic or dental team that you use semaglutide. [2][4]

This is not a full list of side effects. Patients should read the leaflet that comes with their own medicine and ask their prescriber or pharmacist if they are unsure.

Who should not take Wegovy tablets?

Semaglutide may not be appropriate, or may need extra caution, in people who:

• have had an allergic reaction to semaglutide or any ingredient in the medicine;
• Caution: are pregnant, trying to become pregnant or breastfeeding;
• have a history of pancreatitis;
• have severe digestive symptoms or suspected gastroparesis;
• use insulin or sulfonylurea medicines and may be at higher risk of low blood sugar;
• have diabetic eye disease or sudden visual symptoms;
• are due to have surgery, general anaesthetic or deep sedation;
• take medicines where morning timing and absorption are important. [2][3][4]

This does not mean every person in these groups can never use semaglutide. It means the decision should be made through individual clinical judgement, not a simple online checkout.

Does the Wegovy pill work without lifestyle changes?

Wegovy tablets are approved for use alongside a reduced-calorie diet and increased physical activity. The OASIS 4 trial also used lifestyle intervention alongside oral semaglutide. [1][6][7]

That matters because GLP-1 treatment may reduce appetite, but it does not automatically build the habits needed for long-term health. Patients still need to think about protein intake, fibre, hydration, strength training, alcohol intake, sleep, meal structure, emotional eating patterns and what happens if treatment stops.

The medicine may make weight loss more achievable. It should not be framed as a replacement for clinical support or behaviour change.

Is the Wegovy pill available on the NHS?

At the time this guide was prepared, the MHRA stated that Wegovy tablets were approved in the UK but not currently available via the NHS. Decisions on NHS use will follow established processes, including NICE evaluation. [1]

This is separate from existing NICE guidance for injectable semaglutide. NICE currently recommends semaglutide injections for weight management only under specific criteria, including use within a specialist weight management service and defined BMI and comorbidity requirements. [5]

NICE has also published separate guidance on semaglutide for reducing the risk of major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. That guidance concerns semaglutide within its cardiovascular risk-reduction indication and should not be confused with general NHS access to Wegovy tablets for weight management. [12]

Can you get the Wegovy pill privately?

Private treatment should not mean casual treatment. GLP-1 medicines affect appetite, digestion and blood sugar regulation. A safe provider should explain how to take the tablet, what side effects to expect, what symptoms need help, how progress will be reviewed and when treatment should be paused or reconsidered.

How much will the Wegovy pill cost in the UK?

UK pricing should be checked with regulated providers once supply is confirmed. The MHRA approval confirms the medicine’s authorisation, not a universal retail price. Pricing may vary by provider, dose schedule, supply route and the level of clinical support included.

Patients should be cautious about unusually low prices, especially from sellers that do not require a consultation. A safe service has to account for clinical assessment, prescribing, pharmacy supply, follow-up, side-effect advice and appropriate escalation routes.

How to avoid fake or unsafe Wegovy tablets

The growth of GLP-1 medicines has created a market for fake, illegal and unsafe products. The MHRA warns that GLP-1 medicines should not be bought from unregulated sellers, beauty salons, social media, or anywhere that does not involve a healthcare professional consultation. [2]

Avoid any seller that:

• offers Wegovy tablets without a prescription;
• does not require a consultation;
• sells through social media, informal messaging or beauty settings;
• uses pressure tactics or implausibly low pricing;
• cannot show that the medicine is supplied through a regulated pharmacy;
• offers powders, “research chemicals” or compounded products instead of authorised medicines;
• encourages people to hide medical information to qualify.

If a medicine is fake, contaminated, incorrectly dosed or unsuitable, the risks can be serious. Suspected side effects can be reported through the MHRA Yellow Card scheme. [1][2]

Is the Wegovy pill worth waiting for?

It may be worth discussing if injections are the main reason someone has avoided GLP-1 treatment. It may also suit people who prefer daily medication routines and can reliably follow the fasting and waiting instructions.

It may be less suitable for someone who already tolerates injections well, struggles with morning routines, takes several medicines early in the day, or is doing well on another treatment. Waiting for tablets could also delay care for someone who is already eligible for an available treatment and ready to start with appropriate support.

The better question is not “is the tablet better?” It is “which treatment format is safest, most practical and most likely to be used correctly by this person?”

What should patients ask before starting Wegovy tablets?

Caution: a good consultation should cover:

• height, weight and BMI;
• weight-related health conditions;
• previous weight-loss treatments;
• current medicines and supplements;
• diabetes status and blood sugar medicines;
• history of pancreatitis, gallbladder disease or severe digestive symptoms;
• pregnancy, breastfeeding or pregnancy plans;
• upcoming surgery, dental sedation or anaesthesia;
• whether the daily fasting routine is realistic;
• what to do about side effects, missed doses, dose increases, switching and follow-up.

Wegovy tablets are an important development in UK obesity treatment because they give eligible adults another way to use semaglutide. They still need the same seriousness as other GLP-1 medicines: proper prescribing, clear instructions, realistic expectations and ongoing support.